| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda; 2 Department of Diagnostic Science and Pathology, Dental School; and 3 Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Requests for reprints: J. Silvio Gutkind, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Building 30, Room 212, Convent Drive, Bethesda, MD 20892-4330. Phone: 301-496-6259; Fax: 301-402-0823; E-mail: sg39v{at}nih.gov.
Emerging knowledge on how the dysregulated function of signaling networks contributes to the malignant growth of squamous cell carcinoma of the head and neck (HNSCC) can now be exploited to identify novel mechanism-based anticancer treatments. In this regard, we have observed that persistent activation of the serine/threonine kinase Akt is a frequent event in HNSCC, and that blockade of its upstream kinase, 3'-phosphoinositide-dependent kinase 1, potently inhibits tumor cell growth. Akt promotes cell proliferation by its ability to coordinate mitogenic signaling with energy- and nutrient-sensing pathways that control protein synthesis through the atypical serine/threonine kinase, mammalian target of rapamycin (mTOR). This kinase, in turn, phosphorylates key eukaryotic translation regulators, including p70-S6 kinase and the eukaryotic translation initiation factor, 4E binding protein 1. Indeed, we show here that aberrant accumulation of the phosphorylated active form of S6, the most downstream target of the Akt-mTOR-p70-S6 kinase pathway, is a frequent event in clinical specimens from patients with HNSCC and their derived cell lines. Of interest, this enhanced level of the phosphorylated active form of S6 was rapidly reduced in HNSCC cell lines and HNSCC xenograft models at clinically relevant doses of rapamycin, which specifically inhibits mTOR. Furthermore, we observed that rapamycin displays a potent antitumor effect in vivo, as it inhibits DNA synthesis and induces the apoptotic death of HNSCC cells, ultimately resulting in tumor regression. These findings identify the Akt-mTOR pathway as a potential therapeutic target for HNSCC, and may provide the rationale for the early clinical evaluation of rapamycin and its analogues in patients with HNSCC.
This article has been cited by other articles:
|
|
 |
|
  R. Czerninski, P. Amornphimoltham, V. Patel, A. A. Molinolo, and J. S. Gutkind Targeting Mammalian Target of Rapamycin by Rapamycin Prevents Tumor Progression in an Oral-Specific Chemical Carcinogenesis Model Cancer Prevention Research, January 1, 2009; 2(1): 27 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Amornphimoltham, K. Leelahavanichkul, A. Molinolo, V. Patel, and J. S. Gutkind Inhibition of Mammalian Target of Rapamycin by Rapamycin Causes the Regression of Carcinogen-Induced Skin Tumor Lesions Clin. Cancer Res., December 15, 2008; 14(24): 8094 - 8101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Squarize, R. M. Castilho, and J. S. Gutkind Chemoprevention and Treatment of Experimental Cowden's Disease by mTOR Inhibition with Rapamycin Cancer Res., September 1, 2008; 68(17): 7066 - 7072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Amornphimoltham, V. Patel, K. Leelahavanichkul, R. T. Abraham, and J. S. Gutkind A Retroinhibition Approach Reveals a Tumor Cell-Autonomous Response to Rapamycin in Head and Neck Cancer Cancer Res., February 15, 2008; 68(4): 1144 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Patel, B. L. Hood, A. A. Molinolo, N. H. Lee, T. P. Conrads, J. C. Braisted, D. B. Krizman, T. D. Veenstra, and J. S. Gutkind Proteomic Analysis of Laser-Captured Paraffin-Embedded Tissues: A Molecular Portrait of Head and Neck Cancer Progression Clin. Cancer Res., February 15, 2008; 14(4): 1002 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Molinolo, S. M. Hewitt, P. Amornphimoltham, S. Keelawat, S. Rangdaeng, A. Meneses Garcia, A. R. Raimondi, R. Jufe, M. Itoiz, Y. Gao, et al. Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative Clin. Cancer Res., September 1, 2007; 13(17): 4964 - 4973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Patel, H. M. Rosenfeldt, R. Lyons, J.-M. Servitja, X. R. Bustelo, M. Siroff, and J.S. Gutkind Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion Carcinogenesis, June 1, 2007; 28(6): 1145 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-A. O. Nathan, N. Amirghahari, X. Rong, T. Giordano, D. Sibley, M. Nordberg, J. Glass, A. Agarwal, and G. Caldito Mammalian Target of Rapamycin Inhibitors as Possible Adjuvant Therapy for Microscopic Residual Disease in Head and Neck Squamous Cell Cancer Cancer Res., March 1, 2007; 67(5): 2160 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mateo-Lozano, P. C. Gokhale, V. A. Soldatenkov, A. Dritschilo, O. M. Tirado, and V. Notario Combined Transcriptional and Translational Targeting of EWS/FLI-1 in Ewing's Sarcoma. Clin. Cancer Res., November 15, 2006; 12(22): 6781 - 6790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Brown, P. L. Zhang, M. Lun, S. Zhu, P. K. Pellitteri, A. Law, G. C. Wood, and T. L. Kennedy Morphoproteomic and Pharmacoproteomic Rationale for mTOR Effectors as Therapeutic Targets in Head and Neck Squamous Cell Carcinoma Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 273 - 282. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
